Company / Operating Income
KalVista Pharmaceuticals, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$188.0M
FY2025
5-year range
-$188.0M / -$96.6M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#138 of 204
Health Care
What the data says
At -$188M, KalVista Pharmaceuticals, Inc.'s operating income ranks #138 of 204 in the Health Care sector. Declined from -$140M to -$188M over the past 2 years.
Based on SEC 10-K filings.
-$188M in FY2025.
Declined from -$140M to -$188M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#138 of 204 in Health CareTop 68% of 204This company -$188.0M Sector average $107.8M
▼
-274.5% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 0.0% year-over-year.
- Ranks #138 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$188.0M | +0.0% |
| FY2024 | -$188.0M | -33.9% |
| FY2023 | -$140.4M | -26.7% |
| FY2022 | -$110.9M | -14.8% |
| FY2021 | -$96.6M | -66.8% |
| FY2020 | -$57.9M | -159.3% |
| FY2019 | -$22.3M | -47.2% |
| FY2018 | -$15.2M | +18.8% |
| FY2017 | -$18.7M | +16.3% |
| FY2016 | -$22.3M | -176.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026